Tyrosine Kinase Inhibitor

In this video, April Armstrong, MD, MPH, of the Keck School of Medicine at the University of Southern California, Los Angeles, spoke with Healio about the results and clinical implications of the POETYK PSO-1 and POETYK PSO-2 trials.

Evobrutinib, a Bruton’s tyrosine kinase inhibitor that targets B cells and myeloid cells, significantly decreased blood neurofilament light levels as early as 12 weeks in patients with MS, with sustained reductions through 24 weeks.

In this video, Andrew A. Moshfeghi, MD, MBA, discusses results from a phase 1 study of an intravitreal hydrogel axitinib implant for wet AMD he recently presented at the virtual Angiogenesis, Exudation, and Degeneration meeting.

Approximately 29% of older patients with chronic myeloid leukemia did not initiate tyrosine kinase inhibitor therapy within 6 months of diagnosis, according to study results published in Journal of Clinical Oncology.

Gilteritinib and quizartinib were well-tolerated and linked to improved survival and treatment response compared with salvage chemotherapy for relapsed or refractory FLT3 internal tandem duplication-mutated acute myeloid leukemia.

Patients with relapsed or refractory acute myeloid leukemia who received prior tyrosine kinase inhibitor – midostaurin or sorafenib – achieved remission with gilteritinib, an FLT3 inhibitor, according to data presented at ASH Annual Meeting and Exposition.

Treatment with masitinib, a first-in-class tyrosine kinase inhibitor, led to significant improvement in Expanded Disability Scale Status, or EDSS, for patients with MS, according to findings presented at MSVirtual2020.

A randomized phase 3 trial designed to evaluate asciminib as treatment for certain patients with chronic myeloid leukemia met its primary endpoint, according to the agent’s manufacturer.

Vandetanib extended PFS among patients with symptomatic and progressive medullary thyroid cancer, according to results of a post hoc analysis of a randomized phase 3 study published in Journal of Clinical Oncology.

Philadelphia chromosome-positive acute lymphoblastic leukemia is a rare and aggressive form of leukemia characterized by the presence of the BCR-ABL1 fusion.